U.S. Senate Report Says Glaxo Knew that Avandia Increases Risk of Heart Attacks

Glaxo’s FDA-approved study comparing Avandia to Actos is still underway and will eventually enroll 16,000 patients. In the meantime, Glaxo has defended Avandia, saying that the Senate committee took FDA data out of context and that the evidence does not establish increased cardiovascular risks.

| Feb 22, 2010

A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.

The report, released under the names of Senators Max Baucus (D-Mont.) and Charles Grassley (R-Iowa), also questioned why the Food and Drug Administration allowed Glaxo to begin a six-year clinical comparison of Avandia to its commercial rival Actos in 2007, even after years of evidence had accumulated that Avandia seemed to increase the risk of heart attack and heart failure. Glaxo's study, still underway, will eventually enroll 16,000 patients. In the meantime, Glaxo has defended Avandia, saying that the Senate committee took FDA data out of context and that the evidence does not establish increased cardiovascular risks.

According to the Senate report, 500 heart attacks and 300 instances of heart failure could be averted each month if patients currently taking Avandia switched to Actos, a drug manufactured by the Japanese pharmaceutical company Takeda. (In its story on the Senate report, the New York Times said that the FDA had evidence that linked Avandia to 304 deaths during the third quarter of 2009.)

Avandia is the commercial name for rosiglitazone, a member of the family of anti-diabetes drugs known as thiazolidinediones (TZDs), drugs that increase the body's sensitivity to insulin. Actos, the commercial name for pioglitazone, is also a TZD. Both drugs carry warnings about possible side effects on patients' hearts, but Actos has not generated the same level of concern. 

Glaxo's top year with Avandia was in 2006, when it sold more than $3 billion worth of the drug. By 2009, after reports began emerging about its possible link to increased risk of heart attack, sales dropped to $1.2 billion. (In contrast, sales of Actos from April 2008 through March 2009 were $4.4 billion.)  

The FDA is now reviewing data on Avandia and will present its findings this summer to an advisory board that will decide whether Avandia can stay on the market. In 2007, when concerns that Avandia might cause harm to patients' hearts were becoming public, an FDA oversight board voted eight to seven to allow the drug to remain on the market, but also ordered the agency to issue a warning. That warning was followed the next year by Avandia's dramatic drop in sales.

The Senate report is posted here.

* * *


Washington Post

New York Times

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Food, Government & Policy, Heart Care & Heart Disease, Insulin, Medications, Medications Research, Type 2 Issues, Type 2 Medications

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (2)

You May Also Be Interested In...


Posted by Anonymous on 24 February 2010

When will the big companies actually help us.... Diabetes is getting out of control now... Its almost like they want us all to be diabetic.... (or dead)......

Posted by Anonymous on 24 February 2010

This is very disheartening, since we all have to rely on the drug companies to be honest and up front with us. The NYT article at http://www.nytimes.com/2010/02/23/health/23niss.html?sq=nissen%20avandia&st=cse&scp=1&pagewanted=all is very interesting. It seems that GSK was confronted about this issue years ago and chose to dissemble and coverup rather than protect its customers.

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.